Trials / Completed
CompletedNCT03461575
Efficacy and Safety of HU007 Eye Drops in Patients With Dry Eye Syndrome
A Multicenter, Randomized, Double Blind, Restasis®-Controlled Non-inferiority, Moisview® Eye Drops-controlled Superiority, Phase III Study to Evaluate the Efficacy and Safety of HU007 Eye Drops in Patients With Dry Eye Syndrome
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 209 (actual)
- Sponsor
- Huons Co., Ltd. · Industry
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
A multicenter, Randomized, Double blind, Restasis®-controlled Non-inferiority, Moisview® Eye Drops-controlled Superiority, Phase III Study to Evaluate the Efficacy and Safety of HU007 Eye Drops in Patients with Dry Eye Syndrome
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HU007 | cyclosporine 0.02%, trehalose 3% |
| DRUG | Restasis | cyclosporine 0.05% |
| DRUG | Moisview | trehalose 3% |
Timeline
- Start date
- 2018-01-22
- Primary completion
- 2018-07-12
- Completion
- 2018-07-12
- First posted
- 2018-03-12
- Last updated
- 2020-05-08
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT03461575. Inclusion in this directory is not an endorsement.